Skip Navigation


NDT Advance Access originally published online on September 18, 2008
Nephrology Dialysis Transplantation 2008 23(12):3767-3770; doi:10.1093/ndt/gfn517
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/12/3767    most recent
gfn517v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zoccali, C.
Right arrow Articles by Mallamaci, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zoccali, C.
Right arrow Articles by Mallamaci, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Obesity, diabetes, adiponectin and the kidney: a podocyte affair*

Carmine Zoccali and Francesca Mallamaci

Unità Operativa di Nefrologia, Dialisi e Trapianto Renale Ospedali Riuniti and IBIM-CNR, Epidemiologia Clinica e Fisiopatologia delle Malattie Renali e dell’Ipertensione Arteriosa, Reggio Calabria, Italy

Correspondence and offprint requests to: Carmine Zoccali MD, FASN. E-mail: carmine.zoccali@tin.it

Keywords: adiponectin; diabetic nephropathy; insulin; obesity; risk factors

The first 150 words of the full text of this article appear below.



   Introduction
 
Elegant studies by Sharma et al. [26] implicate low adiponectin (ADPN) in the pathogenesis of renal disease in obesity. ADPN-knockout mice exhibited effacement and fusion of podocyte foot processes as well as albuminuria and high oxidative stress in the kidney. ADPN abated albumin permeability in cultured podocytes, and via an AMPK-dependent pathway it induced translocation of zona occludens-1 (ZO-1) to the plasma membrane. Intriguingly, ADPN also reduced NADPH oxidase 4 (Nox4) in podocytes, which is the dominant NADPH oxidase in the kidney. These detailed in vitro studies were corroborated by parallel in vivo studies showing that exogenous ADPN administration to the ADPN null mice reduces albuminuria and oxidative stress and attenuates podocyte damage. Thus, podocytes are a physically distant but quite relevant target of a peculiar product of fat cells such as ADPN. These results provide a novel interpretative framework for obesity-related glomerulopathy and diabetic nephropathy. Drugs that . . . [Full Text of this Article]

Background


   Renal disease in obesity and type 2 diabetes
 


   Adiponectin in CKD
 
Can we exploit ADPN to diagnose and treat obesity- related nephropathy and diabetic nephropathy?

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?